INS and metabolic dysfunction-associated steatotic liver disease: Figure 2 demonstrates adjusted HRs of HCC for joint effects of ALT > 40 U/L and ALD, NAFLD, liver cirrhosis, HBV and HCV infection, and any one of these CLD for entire sample, and stratified by insulin use.